AI and Cancer Research ── 2026-11-14
New papers on cancer and AI, collected from journal feeds, PubMed (searched across all journals) and OpenAlex (a public index used instead of Google Scholar), judged by Jev (an AI that makes language judgements): original research, AI central, which of 13 themes, treatment or trials, and then ranked by importance up to a daily limit. Journals are not filtered by impact factor; each paper shows its journal's IF-equivalent (OpenAlex two-year mean citedness) and the date of that value. Each entry shows the full original abstract.
All cancers: Cancer biology(2)
Hematologic malignancies: AML(0) · CML(0) · ALL(0) · CLL(0) · Lymphoma(1) · Myeloma(0)
Solid tumors: Breast(2) · Lung(2) · Colorectal(1) · Pancreatic(1) · Prostate(0) · Brain(2) · Ovarian(0) · Endometrial(0) · Gastric(0) · Liver(1) · Kidney(0) · Bladder(0)
Rare cancers: ACC(0)
Cancer molecular biology and AI
- Abstract
Accurate and effective treatment of solid tumors has long been a core issue in cancer therapy. Antibody-drug conjugates (ADCs) represent a crucial breakthrough in precision oncology. Traditional ADCs rely on monoclonal antibodies generated through animal immunization, followed by screening, sequencing, and recombinant expressiona process that is experimentally complex and costly. In this study, we employed deep learning-based computational design methods to design mini-protein binders targeting the tumor-associated antigen TROP2. The designed TROP2 mini-protein binder exhibited high specificity and thermal stability. The binding affinity was optimized from 40.4 nM to 628 pM through partial diffusion. On this basis, we engineered the mini-protein binder by conjugating it with the microtubule inhibitor VcMMAE, thereby constructing mini-protein drug conjugates (MPDCs) that can specifically target and kill TROP2-positive tumor cells. A comprehensive assessment of the anti-tumor efficacy of these MPDCs was performed using cancer cell lines, organoid models, and mouse xenograft models.
Journal IF-equivalent: 8.4 (OpenAlex 2-year mean citedness, value as of 2026-11-12, retrieved 2026-11-13; not the official Clarivate IF)Reference: Xue T, Li N, Yang Z, Tang J, Ding Y, Pan J, et al. Design of High-Affinity Mini-Protein Drug Conjugates Targeting TROP2. Journal of Medicinal Chemistry. 2026 Nov 11 [Epub ahead of print]. doi:10.1021/acs.jmedchem.6c02191.Checked: Abstract only - Abstract
OBJECTIVES: Artificial Intelligence (AI) has the potential to transform clinical medicine by enhancing diagnostic precision, prognostic accuracy, and personalized decision making. In urological oncology, AI technologies are increasingly integrated across diagnostic, prognostic, and therapeutic pathways. This overview of systematic reviews aims to synthesise the current evidence on the performance and clinical utility of AI applications in urological malignancies. METHODS: A systematic search was conducted of major bibliographic databases from 1974 to October 2024 to identify systematic reviews (SRs) evaluating AI-based models in urological cancers. We followed the Cochrane methodology of Overviews of Reviews. Outcomes of interest included diagnostic accuracy metrics (area under the receiver operating characteristic curve [AUC-ROC], sensitivity, specificity, and accuracy) and predictive performance for treatment-relatedoutcomes. RESULTS: A total of 67 SRs encompassing 1139 primary studies were included. RoB was assessed as low in 21 reviews, high in 41, and unclear in 5. Forty-five SRs evaluated AI in prostate cancer (PCa). AI models demonstrated high accuracy (88-93%) in distinguishing benign from malignant lesions, and outperformed human interpretation alone in predicting clinically significant PCa (AUC: 0.933 vs. AUC: 0.82-0.87). Performance in Gleason score classification was also very strong (AUC: 0.72-0.99, Accuracy: 70.8-93.0%). Sixteen SRs assessed AI in Renal carcinoma (RCa), reporting accurate subtype classification and tumor grade prediction, with some models exceeding 90% accuracy. Sixteen SRs focused on Bladder Cancer (BCa), showing improved detection of muscle-invasive disease and recurrence risk prediction compared with the conventional approach. Key limitations included heterogeneity in validation strategies, overlap of primary studies across reviews, and potential oversampling due to synthetic or augmented data. CONCLUSIONS: AI-based models consistently demonstrate improved diagnostic and predictive performance across urological malignancies and hold promise for enhancing clinical decision-making and patient outcomes. At present, AI tools should be regarded as decision-support systems that complement, rather than replace, clinical expertise. Future research should emphasize prospective validation, standardized outcome definitions, and evaluation of real-world clinical impact. Robust and harmonized evaluation frameworks are also essential to address challenges related to data quality, privacy, generalizability, and ongoing regulatory and legal uncertainty, thereby enabling safe and equitable integration of AI into routine urological cancer care.
Journal IF: unknown (could not be matched)Reference: Sakalis V, Chatzigriva E, Pang KH, Rai BP, Filippidis I, Moris L, et al. The role of artificial intelligence in urological malignancies: an overview of systematic reviews. Can J Urol. 2026;33(5):1061-87. doi:10.32604/cju.2026.077632. PMID: 43016012.Checked: Abstract only
See all 2 Cancer biology papers →
Hematologic malignancies
Acute myeloid leukemia (AML): treatment, trials and AI
No new qualifying paper for this issue.
Chronic myeloid leukemia (CML): treatment, trials and AI
No new qualifying paper for this issue.
Acute lymphoblastic leukemia (ALL): treatment, trials and AI
No new qualifying paper for this issue.
Chronic lymphocytic leukemia (CLL): treatment, trials and AI
No new qualifying paper for this issue.
Lymphoma: treatment, trials and AI
- Abstract
PURPOSE: To assess if AI-assisted segmentation on [ 18 F]FDG PET/CT significantly reduces time in quantifying Total Metabolic Tumor Volume (TMTV) and the greatest distance between two lesions (Dmax) in Large B-cell lymphoma (LBCL) patients. METHODS: A retrospective study at two institutions included 56 LBCL patients (Ann-Arbor staging: 14% with no disease, 25% stage I-II, 61% stage III-IV). Two methods were compared: AI-assisted segmentation (Pionus ® v1.1.0, PAIRE, Paris) automatically identified lesions with expert correction of AI errors, while expert-led segmentation was fully manual. Both methods used a 41% SUVmax threshold. RESULTS: AI-assisted segmentation was 41% faster, saving an average of 104 s per patient (152 ± 134 s vs. 255 ± 270 s, p < 0.001), with time saved correlating with TMTV (r = 0.67, p < 0.001). No significant differences in TMTV or Dmax were found between methods. Intraclass correlation coefficients were high for both TMTV (0.91 and 0.95) and Dmax (0.97 and 0.95), with strong inter-reader agreement. CONCLUSION: AI-assisted segmentation significantly reduces time for TMTV and Dmax measurement in LBCL patients, especially in patients with high tumor burden, while maintaining high reliability and inter-reader agreement. The impact on the integrated clinical workflow has yet to be assessed.
Journal IF-equivalent: 3.7 (OpenAlex 2-year mean citedness, value as of 2026-11-04, retrieved 2026-11-05; not the official Clarivate IF)Reference: Micheletti V, Marchal É, Gambiez M, Dercle L, Meyer ME, Palard-Novello X, et al. AI-assisted [18F]FDG PET/CT quantification: a time-saving approach in large B-cell lymphoma?. EJNMMI Phys. 2026 Aug 16;13(1):106. doi:10.1186/s40658-026-00923-y. PMID: 43015420.Checked: Abstract only
Multiple myeloma: treatment, trials and AI
No new qualifying paper for this issue.
Solid tumors
Breast cancer: treatment, trials and AI
- Abstract
Upstaging from pure ductal carcinoma in situ (DCIS) to invasive carcinoma occurs in a significant proportion of patients diagnosed by core needle biopsy, which alters surgical management, particularly the need for sentinel lymph node biopsy. Although preoperative MRI is widely used to detect occult invasion, its diagnostic performance remains controversial, with reported sensitivities and specificities varying significantly across the literature. Therefore, this systematic review and meta-analysis aimed to assess the diagnostic performance of conventional MRI semantic features and MRI-based AI models in predicting the upstaging of DCIS to invasive carcinoma. The results of this study will clarify the clinical utility of MRI in preoperative risk stratification and inform future related studies.
Journal IF: unknown (could not be matched)Reference: [No authors listed]. From Conventional MRI Features to Artificial Intelligence: A Systematic Review and Meta-analysis of MRI Predictors for Occult Invasion in Biopsy-confirmed Ductal Carcinoma in Situ. Open Science Framework. [Epub ahead of print]. doi:10.17605/osf.io/7qgmd.Checked: Abstract only - Abstract
Accurate molecular subtyping of breast cancer is essential for personalized therapy, yet inconsistencies between biopsy and postoperative immunohistochemistry (IHC) due to tumor heterogeneity and sampling limitations pose clinical challenges. We developed Ultrasound-Guided Pathomic Subtyping (US-GPS), a cross-modal framework enabling subtype prediction using ultrasound (US) alone, guided by IHC-stained whole-slide images (WSIs) during training. A total of 1283 patients from four centers were retrospectively included, with 454 cases (paired US and WSIs) for model training/validation and 829 US-only cases for external testing. US-GPS aligned WSI-derived patch- and region-level features (from HER2, ER, PR, Ki-67 IHC stains) with handcrafted and deep US features via co-attention and contrastive learning. Using US alone, the model achieved an AUROC of 0. 966 (95% CI 0.960-0.991) in internal validation, comparable to pathology-only (0. 971) and joint models (0.980), and superior to US-only (0.861). Performance remained robust across both internal (AUROC range: 0.930-0.942) and all external cohorts (AUROC range: 0.915-0.963). US-GPS enables scalable, non-invasive, and interpretable subtype classification, with potential for both pre-treatment decision-making and longitudinal monitoring of molecular phenotypic shifts.
Journal IF-equivalent: 9.8 (OpenAlex 2-year mean citedness, value as of 2026-11-04, retrieved 2026-11-05; not the official Clarivate IF)Reference: Zou WJ, Zheng LF, Feng BJ, Yao JC, Wu YX, Lv LJ, et al. Ultrasound-guided deep learning framework with whole slide images for molecular subtyping of breast cancer: a multicentre, retrospective study. NPJ Precis Oncol. 2026 Jul 22;10(1):435. doi:10.1038/s41698-026-01612-w. PMID: 43015298.Checked: Abstract only
Lung cancer: treatment, trials and AI
- Abstract
This study aimed to develop and validate an interpretable machine learning (ML) model that integrates clinical data, normalized distance from the metabolic hotspot to the tumor centroid (NHOC) / normalized distance from the metabolic hotspot to the tumor perimeter (NHOP) metrics, and PET/CT habitat radiomics to predict recurrence in lung adenocarcinoma (LUAD) and perform postoperative risk stratification. In this retrospective study, we analyzed patients with resectable stage Ⅰ LUAD from two hospitals and a public dataset, comprising a training cohort ( n = 253) and an internal validation cohort ( n = 106), including a subset with radiogenomics data ( n = 26). NHOC and NHOP were extracted using LIFEx software. Nine machine learning algorithms were evaluated to identify the optimal radiomics features. The best-performing algorithm was used to construct predictive models incorporating clinical variable, NHOC/NHOP, and habitat-based radiomics features. Shapley Additive Explanations (SHAP) were employed to interpret model contributions, while paired RNA-sequencing explored potential biological pathways. Smoking history and NHOCpeak were identified as independent predictors constituting the clinical model. The combined model demonstrated moderate discrimination performance for recurrence prediction. achieved an AUC of 0.876 (95% CI: 0.824–0.929) in the training cohort (Sensitivity: 0.890, Specificity: 0.720, PPV: 0.565, NPV: 0.942) and an AUC of 0.794 (95% CI: 0.671–0.918) in the internal testing cohort (Sensitivity: 0.833, Specificity: 0.750, PPV: 0.568, NPV: 0.919). NHOCpeak was the highest-ranked individual predictor in the SHAP analysis, whereas RadScore summarized the aggregate contribution of the radiomic features. The hybrid model successfully stratified patients into distinct risk groups for recurrence-free survival (RFS). Notably, the high-risk group showed enrichment in pathways related to motor proteins and neuroactive ligand-receptor interactions. This study presents exploratory findings of an interpretable machine learning model with moderate discrimination for the postoperative prediction of recurrence in stage I LUAD. NHOC emerged as a promising, novel independent predictor, providing significant added prognostic value beyond classical PET parameters.
Journal IF-equivalent: 5.7 (OpenAlex 2-year mean citedness, value as of 2026-11-04, retrieved 2026-11-05; not the official Clarivate IF)Reference: Xue B, Ji W, Wang L, Zheng X, Wang L, Zhang S, et al. Interpretable PET/CT habitat radiomics integrates novel metabolic metrics for postoperative risk stratification in stage I lung adenocarcinoma. Cancer Imaging. 2026 Nov 10 [Epub ahead of print]. doi:10.1186/s40644-026-01158-x.Checked: Abstract only - Abstract
BACKGROUND: Histological grading of lung adenocarcinoma is limited by interobserver variability, particularly when distinguishing noninvasive lepidic growth from invasive patterns. This distinction depends on evaluation of the alveolar elastic fiber framework, which is often insufficiently visualized on routine hematoxylin and eosin (H&E) slides. METHODS: We developed a deep learning framework to improve grading objectivity by computationally visualizing elastic fiber-related architecture from standard H&E images. A dual-stream EfficientNet-B0 classifier was trained using spatially coregistered H&E and eosin-based elastin fluorescence (EBEF) images. To enable clinical deployment without additional staining or fluorescence microscopy, a Pix2Pix-HD generative adversarial network was trained to synthesize high-fidelity virtual EBEF images from H&E alone. The resulting automated pipeline classified histological patterns, quantified pattern proportions, and assigned tumor grades. Performance was evaluated on independent multicenter cohorts, with ablation analyses assessing key pipeline components. Prognostic relevance was explored using a curated TCGA lung adenocarcinoma cohort. RESULTS: The benchmark dual-stream model using real H&E and EBEF achieved 89.3% tile-level classification accuracy. Using virtual EBEF images, the automated grading pipeline achieved 94.2% accuracy on an external validation cohort, outperforming an H&E-only model (79.6%). Ablation studies confirmed that performance gains depended on informative multimodal input, accurate spatial registration, and attentive feature fusion. AI-assigned grades demonstrated a consistent trend toward association with overall survival in TCGA, with significant stratification observed when low-grade tumors were combined (log-rank p = 0.048). CONCLUSIONS: This framework enables objective grading of lung adenocarcinoma from a single routine H&E slide by enhancing visualization of elastic fiber-related architecture. The approach improves grading consistency and prognostic stratification without altering standard pathology workflows.
Journal IF-equivalent: 4.2 (OpenAlex 2-year mean citedness, value as of 2026-11-06, retrieved 2026-11-07; not the official Clarivate IF)Reference: Wang CL, Lei SP, Lu Y, Zou LF, Xiong JB, Li JW, et al. Deep learning-powered virtual eosin-based elastic fiber framework imaging improves objective grading and prognostic stratification of lung adenocarcinoma. Diagn Pathol. 2026 Aug 17;21(1):92. doi:10.1186/s13000-026-01837-0. PMID: 43015879.Checked: Abstract only
Colorectal cancer: screening, treatment, trials and AI
- Abstract
BACKGROUND: The rising incidence and poor prognosis of early-onset colorectal cancer (EOCRC) highlight an urgent need for effective diagnostic biomarkers. This study integrates RNA sequencing data with machine learning algorithms to identify EOCRC-specific genes and construct a diagnostic model to improve molecular diagnosis and explore the functional role of key genes. METHODS: We analyzed RNA sequencing data from EOCRC patients (age ≤ 50) obtained from the Gene Expression Omnibus (GEO) database. The differentially expressed genes (DEGs) between EOCRC and normal tissues were identified and subjected to construct a diagnostic model through random forest analysis and artificial neural network modeling. The diagnostic performance of the model was evaluated in a training set and validated in an independent set. CIBERSORT was utilized to investigate the immune cell infiltration patterns. The expression levels of key DEGs were further verified in 15 paired clinical tissues. Moreover, RT-qPCR and western blotting were applied to detect the expression of solute carrier member 26 family 2 (SLC26A2), which is one of the top-ranked genes, in CRC cell lines. The functional role of SLC26A2 was investigated in EOCRC cell lines (SW480 and HT29) through lentivector-mediated ectopic overexpression experiments assessing proliferation, migration and invasion. The association between SLC26A2 and the cytotoxicity of vanadium-containing compounds (BMOV, VO(acac)₂) was explored, focusing on redox modulation (ROS/GSH levels) using inhibitors (BSO) and antioxidants (NAC). RESULTS: We identified 22 DEGs between EOCRC tumor and normal tissues. A machine learning-based diagnostic model based on seven DEGs (SLC26A2, FCGBP, SLC7A5, CA2, STC2, SLC4A4 and THBS2) for EOCRC was constructed. The model achieved an AUC of 0.987 (training) and 0.874 (validation). Immune profiling revealed altered infiltration of monocytes, M0 macrophages, and γδ T cells in EOCRC. Experimental validation confirmed the dysregulation of the seven key genes. SLC26A2 was downregulated in EOCRC tissues and its overexpression significantly inhibited cell proliferation, migration, and invasion in vitro. Transcriptomic analysis linked SLC26A2 overexpression to glutathione (GSH) metabolism. EOCRC cells exhibited sensitivity to vanadium compounds, which was enhanced by SLC26A2 overexpression. SLC26A2 expression correlated with compound-induced cytotoxicity alongside modulation of ROS/GSH levels, as evidenced by the synergistic effect of BSO (GSH inhibitor) and the attenuating effect of NAC (antioxidant). CONCLUSIONS: We developed and validated a robust machine learning-based diagnostic model for EOCRC using a 7-gene signature. The downregulated gene SLC26A2 acts as a tumor suppressor in EOCRC and is associated with cellular sensitivity to vanadium-containing compounds, potentially through a redox-dependent mechanism linked to GSH metabolism. These findings provide novel insights into the identification of diagnostic biomarkers and highlight the therapeutic potential for EOCRC.
Journal IF-equivalent: 4.8 (OpenAlex 2-year mean citedness, value as of 2026-11-12, retrieved 2026-11-13; not the official Clarivate IF)Reference: Yin M, Zhao H, Zhang X, Geng X, Liu Y, Zhang S, et al. A seven-gene signature diagnostic model for early-onset colorectal cancer and the tumor-suppressive role of SLC26A2 via redox modulation. BMC Cancer. 2026 Aug 13;26(1):1387. doi:10.1186/s12885-026-16714-8. PMID: 43009819; PMCID: PMC13753126.Checked: Full text checked
Pancreatic cancer: treatment, trials and AI
- Abstract
BACKGROUND: Computed tomography (CT) stages pancreatic ductal adenocarcinoma (PDAC) but does not read out the treatment-guiding tumour biology, requiring biopsy. Whether an imaging-biology relationship discovered in preclinical MRI holds independently in human CT is unknown. METHODS: One pipeline was applied to two PDAC cohorts: longitudinal 9.4 T multi-parametric MRI (169 sessions; 1002 image series, 471 quantitative maps) with terminal histopathology in male C57BL/6 mice bearing orthotopic KPC-derived tumours treated with gemcitabine, a dendritic-cell vaccine, both, or neither, and abdominal CT with matched proteogenomics from CPTAC-PDA. Radiomics and frozen foundation-model embeddings were modelled under grouped cross-validation against five pre-specified paired endpoints, with no cross-species transfer of features, weights, or labels. FINDINGS: Applied independently, the pipeline recovered four matched molecular endpoints in both species (CD8 infiltration, stromal collagen, CD8:CD68 immune balance, cytolytic activity), with areas under the receiver-operating-characteristic curve (AUROCs) of 0.938-0.960 in mice and 0.780-0.856 in humans. Survival concordance indices were 0.729 and 0.689. After adjustment for age, stage, and grade, the human imaging score remained independently prognostic (hazard ratio 1.87 per SD, 95% CI 1.32 to 2.66; p < 0.001 [Wald test]; combined concordance index 0.726 versus 0.611 for clinical covariates). Findings held in portal-venous-restricted analysis; frozen embeddings outperformed end-to-end fine-tuning in both arms. INTERPRETATION: One pipeline recovered matched PDAC biology in mouse MRI and human CT, supporting preclinical imaging to nominate non-invasive CT biomarker candidates for biopsy-sparing PDAC trial stratification, pending prospective external validation. FUNDING: National Cancer Institute; Society of Interventional Radiology Foundation; University of California Irvine Anticancer Challenge Pilot grant.
Journal IF-equivalent: 12.5 (OpenAlex 2-year mean citedness, value as of 2026-11-12, retrieved 2026-11-13; not the official Clarivate IF)Reference: Yu G, Zhang Z, Eresen A, Hou Q, Wei P, Hou X, et al. Foundation-model imaging biomarkers for pancreatic cancer: cross-species discovery of conserved tumour biology in mouse MRI and human CT. EBioMedicine. 2026 Dec;134:106545. doi:10.1016/j.ebiom.2026.106545. PMID: 43013920.Checked: Abstract only
Prostate cancer: treatment, trials and AI
No new qualifying paper for this issue.
Brain tumours: treatment, trials and AI
- Abstract
BACKGROUND: O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography ([ 18 F]FET PET) is clinically useful in neuro-oncology but limited by cost and availability. We assessed the clinical utility of magnetic resonance imaging (MRI)-derived synthetic [ 18 F]FET PET. METHODS: A total of 489 patients with histologically confirmed gliomas or brain metastases were retrospectively analyzed. A deep learning model generated synthetic PET images from multimodal MRI in the overall cohort and subgroups. Synthetic PET was evaluated against reference PET for image similarity by peak signal-to-noise ratio (PSNR) and structural similarity index (SSIM), standardized uptake value ratio (SUVR) analysis by Pearson correlation and Bland-Altman analysis, and blinded reader assessment for glioma grading and high-grade glioma (HGG) versus solitary brain metastasis (SBM) differentiation using receiver operating characteristic analysis with area under the curve (AUC). RESULTS: Synthetic PET showed high similarity to reference PET in the overall, glioma, and metastasis groups (PSNR, 34.7-35.5 dB; SSIM, 0.90-0.96), and SUVR correlations were strong (r = 0.77-0.93, all P 0.05). CONCLUSIONS: MRI-derived synthetic [ 18 F]FET PET may enhance glioma grading and HGG-SBM differentiation, providing a PET-like alternative when FET PET is unavailable.
Journal IF-equivalent: 2.8 (OpenAlex 2-year mean citedness, value as of 2026-11-12, retrieved 2026-11-13; not the official Clarivate IF)Reference: Liang X, Yao C, Diao H, Xiao K, Li F, Lu J. MRI-derived synthetic [¹⁸F]FET PET in neuro-oncology: evaluation in glioma grading and differentiation from solitary brain metastasis. Neuroradiology. 2026 Nov 11 [Epub ahead of print]. doi:10.1007/s00234-026-04266-4. PMID: 43015482.Checked: Abstract only - Abstract
Background and objectivePreoperative identification of fibrous meningioma may help inform surgical planning.We compared contrast-enhanced T1-weighted imaging (T1CE) and fluid-attenuated inversion recovery (FLAIR) radiomics, TabPFN and voxel-input three-dimensional convolutional neural networks (CNNs), and imaging-clinical candidate models.We also evaluated training-only controls and regional-clinical fusion. MethodsThis single-center retrospective study screened 529 records from May 2018 to September 2026 and included 64 cases of World Health Organization (WHO) grade 1 meningioma (18 fibrous and 46 non-fibrous), of which 44 were used for training and 20 for internal evaluation.Automated segmentation and manual quality control defined the tumor and interface regions.In group-aware validation, clinical-only and matched-input classifiers, probability ensembles, and BIG-Huang regional fusion all used a fixed 44/20 split, and all preprocessing and selection were confined to the training data.Performance was assessed at a threshold of 0.5 with 2,000 outcome-stratified bootstrap resamples.Agreement between repeated volume measurements was assessed in 30 cases. ResultsIn the sequence/CNN benchmark, the six-feature and two-feature imaging-clinical candidate models had areas under the curve (AUCs) of 0.810 (95% conditional confidence interval (CI): 0.524-1.000)and 0.905 (0.726-1.000), respectively.Both models had true negatives (TN) = 12, false positives (FP) = 2, false negatives (FN) = 2, and true positives (TP) = 4.In group-aware validation, the five-feature combined TabPFN model had an AUC of 0.726 (0.464-0.929).In the structurally matched BIG-Huang TabPFN regional/fusion models, adding nine clinical variables increased the AUC from 0.702 (0.429-0.905) to 0.833 (0.619-0.976) and reduced the Brier score from 0.234 to 0.151.The 11-input candidate model had an outer out-of-fold (OOF) AUC of 0.422 (0.231-0.625) in the training set.The intra-observer and inter-observer volume intraclass correlation coefficients (ICCs) were 0.9836 and 0.9655, respectively. ConclusionsThis study describes the complementarity of MRI and clinical information through direct-input and regional-score models.The BIG-Huang analysis supports further investigation of regional-clinical integration.Model probabilities require independent calibration assessment before they are used in individual clinical risk communication.
Journal IF-equivalent: 1.2 (OpenAlex 2-year mean citedness, value as of 2026-10-25, retrieved 2026-10-26; not the official Clarivate IF)Reference: Zhu F, Ma H, Tang S, Zou S, Ma H, Guo H. Preoperative Prediction of Fibrous Meningioma Using Contrast-Enhanced T1-Weighted Radiomics and a Tabular Foundation Model: A Single-Center Retrospective Study. Cureus. 2026 Nov 10 [Epub ahead of print]. doi:10.7759/cureus.119408.Checked: Abstract only
Ovarian cancer: treatment, trials and AI
No new qualifying paper for this issue.
Endometrial cancer: treatment, trials and AI
No new qualifying paper for this issue.
Gastric cancer: treatment, trials and AI
No new qualifying paper for this issue.
Liver cancer: treatment, trials and AI
- Abstract
BACKGROUND: Ki-67 is a key immunohistochemical marker of tumor proliferative activity in hepatocellular carcinoma (HCC); however, non-invasive assessment of Ki-67 status before surgery remains an unmet clinical need. This study aimed to develop and internally validate multi-sequence magnetic resonance imaging (MRI) radiomics models based exclusively on non-contrast sequences for preoperative prediction of Ki-67 expression. METHODS: This retrospective study included 91 patients with 97 pathologically confirmed HCC lesions ( high Ki-67, ≥ 10%, n = 55; low Ki-67, < 10%, n = 42). Three-dimensional volumes of interest were manually segmented on T2-weighted imaging ( T2WI), diffusion-weighted imaging ( DWI), and apparent diffusion coefficient ( ADC) maps, and 5055 radiomic features ( approximately 1684 per sequence) were extracted were extracted from the three sequences. After feature selection with Pearson correlation coefficient filtering and the Kruskal-Wallis test, three multilayer perceptron ( MLP) models were constructed: Model-T ( T2WI), Model-D ( DWI + ADC), and Model-M ( combined T2WI, DWI, and ADC). The models were developed with five-fold cross-validation in the training cohort and were evaluated in a held-out testing cohort. This was a single-center retrospective study, and validation was internal only. Model performance was assessed using the area under the receiver operating characteristic curve ( AUC), sensitivity, specificity, and accuracy. RESULTS: No significant differences in clinical characteristics were observed between the high and low Ki-67 groups. In the training cohort, the apparent (resubstitution) AUCs of Model-T, Model-D, and Model-M were 0.715, 0.823, and 0.860, respectively (representing model fit rather than cross-validated performance). In the held-out testing cohort, the corresponding AUCs were 0.707, 0.692, and 0.716. In the testing cohort, Model-M achieved a sensitivity of 68.8%, a specificity of 53.8%, and an accuracy of 62.1%, whereas Model-D showed the most balanced performance (sensitivity, 68.8%; specificity, 76.9%; accuracy, 72.4%). The dominant features were texture features derived predominantly from the ADC sequence. The cross-validated training AUCs were considerably lower (range, 0.522-0.585). CONCLUSIONS: In this single-center, internally validated study, non-contrast multi-sequence MRI radiomics models integrating T2WI, DWI, and ADC showed moderate discrimination of Ki-67 expression in HCC. The contrast-free strategy is potentially applicable to patients with contraindications to gadolinium and warrants external validation; These findings represent internal validation only and require confirmation in external, preferably prospective multicenter, cohorts before any clinical application can be considered.
Journal IF-equivalent: 3.1 (OpenAlex 2-year mean citedness, value as of 2026-11-12, retrieved 2026-11-13; not the official Clarivate IF)Reference: Zhang Y, Bao Y, Huang G, Luo J, Chen X, Wu L, et al. Preoperative prediction of Ki-67 expression in hepatocellular carcinoma using multi-sequence MRI radiomics: a non-contrast approach integrating T2-weighted, diffusion-weighted, and apparent diffusion coefficient imaging. Abdom Radiol (NY). 2026 Nov 11 [Epub ahead of print]. doi:10.1007/s00261-026-05857-8. PMID: 43012972.Checked: Abstract only
Kidney cancer: treatment, trials and AI
No new qualifying paper for this issue.
Bladder cancer: treatment, trials and AI
No new qualifying paper for this issue.
Rare cancers
Adenoid cystic carcinoma: treatment, trials and AI
No new qualifying paper for this issue.